Has John Linfoot received payments from drug or device companies?

Yes. Drug and device makers reported $3,755 in general payments to John Linfoot across 142 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Linfoot did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Linfoot come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Linfoot

Nuclear Imaging & Therapy · Lafayette, CANPI 1972551679

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,690 and has fallen 96.6% since, to $58 in 2024.

$3,755in general payments, 2019–2025

Across 142 payments — averaging $26.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$780
Amarin Pharma, Inc.$624
Novo Nordisk$321
Amgen$231
Radius Health, Inc.$227
Lilly USA, LLC$180
plus $1K from 17 others

What the payments were for

Food & beverage$3,70899%
Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	26	$780
Amarin Pharma, Inc.	27	$624
Novo Nordisk	11	$321
Amgen	7	$231
Radius Health, Inc.	7	$227
Lilly USA, LLC	5	$180
Corcept Therapeutics	1	$165
Endo Pharmaceuticals Inc.	7	$162
Mannkind Corporation	7	$153
Sanofi-aventis U.S. LLC	1	$125
AbbVie	7	$114
Xeris Pharmaceuticals, Inc.	5	$101
IBSA Pharma Inc.	5	$101
Boehringer Ingelheim	6	$93
Shire North American Group Inc	4	$77
Ferring Pharmaceuticals Inc.	3	$70
Abbott	4	$65
Dexcom, Inc.	3	$45
Companion Medical, Inc.	2	$44
Takeda Pharmaceuticals U.S.A., Inc.	1	$21
Tandem Diabetes Care, Inc.	1	$20
Insulet Corporation	1	$19
Merck	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear imaging & therapy providers in Californiato place this figure against a meaningful peer group, so we don't.

Other nuclear imaging & therapy in Lafayette

Jeremie CalaisLos Angeles$131K
Maria GuevaraNorth Hollywood$2K
Holly Marciniak ThompsonSanta Clara$391
Frederick WeilandRoseville$332
Chiayi NiSylmar$210
Ryan ReddyIrvine$208
Jocelyn EspirituModesto$127
Evelyn MusniFremont$114
John WhiteRancho Palos Verdes$34
Eugene SilvermanSan Diego$20

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →